Patents by Inventor David L. Foster
David L. Foster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931570Abstract: Flexible catheters adapted to be inserted into a body to deliver high-voltage, fast (e.g., microsecond, sub-microsecond, nanosecond, picosecond, etc.) electrical energy to target tissue may include a plurality of conductive layers, that may be coaxial. These catheters and method of using them to treat tissue are configured to reduce or avoid arcing.Type: GrantFiled: January 3, 2023Date of Patent: March 19, 2024Assignee: Pulse Biosciences, Inc.Inventors: David J. Danitz, Kevin L. Moss, Wesley C. Joe, Christopher J. Foster, Gary L. Boseck, Xitlalic Y. Soto-Sida, Robert Maston, John P. Lunsford
-
Patent number: 7211560Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: GrantFiled: December 29, 2003Date of Patent: May 1, 2007Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Patent number: 6962795Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: November 10, 1993Date of Patent: November 8, 2005Assignee: Dendreon CorporationInventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Publication number: 20040259769Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: ApplicationFiled: December 29, 2003Publication date: December 23, 2004Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Patent number: 6818616Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: May 26, 1995Date of Patent: November 16, 2004Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 6756211Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: May 11, 1993Date of Patent: June 29, 2004Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 6670323Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: GrantFiled: November 10, 2000Date of Patent: December 30, 2003Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Patent number: 5919900Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: May 26, 1995Date of Patent: July 6, 1999Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster
-
Patent number: 5789178Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: June 2, 1995Date of Patent: August 4, 1998Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 5747296Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: December 23, 1993Date of Patent: May 5, 1998Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 5708141Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Such compositions may comprise a glycoprotein isolated from nematodes, particularly of the genus Ancylostoma. These compositions are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: May 24, 1994Date of Patent: January 13, 1998Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 4389586Abstract: The magnet frame of a dynamoelectric machine comprises a removable, generally cylindrical inner member concentrically disposed inside a cylindrical outer member. The inner member is supported in a cantilever fashion at only one of its ends, and most of its outside surface is normally separated by a relatively small circumferential gap from the cooperating inside surface of the outer member. The outer member of the frame rotatably supports the hub of a motorized wheel, which hub is coupled via a torque tube and gearing to a rotor inside the inner member. Conventional means is provided in the inner member for producing a field of magnetic flux in both the magnet frame and the rotor, and the path of this flux will include parallel branches in the inner and outer frame members.Type: GrantFiled: February 22, 1982Date of Patent: June 21, 1983Assignee: General Electric CompanyInventors: David L. Foster, John F. Haupt, Malcolm W. Waite